REGN
Regeneron Pharmaceuticals Inc
NASDAQ: REGN · HEALTHCARE · BIOTECHNOLOGY
$612.14
+0.11% today
Updated 2026-06-12
Market cap
$63.21B
P/E ratio
14.73
P/S ratio
4.24x
EPS (TTM)
$40.94
Dividend yield
0.60%
52W range
$474 – $819
Volume
0.9M
WallStSmart proprietary scores
64
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+8.5
Quality
A7.5
Profitability
B+8.0
Valuation
A2/9
Piotroski F-Score
Weak
4.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$821.08
+34.13%
12-Month target
$741.53
+21.14%
Intrinsic (DCF)
$1,350.89
Margin of safety
+52.96%
5 Strong Buy16 Buy8 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.44 — safe zone
+ Profit margin 29.60% — above average
+ Free cash flow $848.30M — positive
+ Revenue growth 19.00% QoQ
+ 52.96% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $12.17B | $13.12B | $14.20B | $14.34B | $14.92B | $16.1B |
| Net income | $4.34B | $3.95B | $4.41B | $4.50B | $727.20M | — |
| EPS | — | — | — | — | $40.94 | $46.75 |
| Free cash flow | $4.42B | $3.67B | $3.66B | $4.08B | $848.30M | — |
| Profit margin | 35.64% | 30.14% | 31.07% | 31.41% | 29.60% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-01 | RYAN, ARTHUR F | Sale | 24 | $703.46 |
| 2026-05-01 | RYAN, ARTHUR F | Sale | 15 | $702.46 |
| 2026-05-01 | RYAN, ARTHUR F | Sale | 14 | $705.56 |
Peer comparison
Smart narrative
Regeneron Pharmaceuticals Inc trades at $612.14. representing a P/E of 14.73x trailing earnings. Our Smart Value Score of 64/100 indicates the stock is good. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 4.44, it sits in the safe zone. TTM revenue stands at $14.92B. with profit margins at 29.60%. Our DCF model estimates intrinsic value at $1,350.89.
Frequently asked questions
What is Regeneron Pharmaceuticals Inc's stock price?
Regeneron Pharmaceuticals Inc (REGN) trades at $612.14, on a P/E of 14.7x and a P/S of 4.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Regeneron Pharmaceuticals Inc overvalued?
Regeneron Pharmaceuticals Inc carries a Smart Value Score of 64/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $1,350.89 versus the $612.14 price, a 53.0% margin of safety on a cash flow basis.
What is the price target of Regeneron Pharmaceuticals Inc (REGN)?
The 12-month analyst consensus target is $821.08, about 34.1% above the current $612.14. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of REGN by 2030?
Our research-backed model puts the 2030 base case at $2,518.03, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Regeneron Pharmaceuticals Inc (REGN)?
Our DCF model estimates intrinsic value at $1,350.89, a +53.0% margin of safety versus today's $612.14. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Regeneron Pharmaceuticals Inc's revenue?
Regeneron Pharmaceuticals Inc's trailing twelve-month revenue is $14.92B, and our model projects it reaching about $22.40B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Regeneron Pharmaceuticals Inc's Altman Z-Score is 4.44, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.24x
ROE14.08%
Beta0.30
50D MA$714.01
200D MA$695.10
Shares out0.10B
Float0.10B
Short ratio—
Avg volume0.9M
Performance
1 week+0.00%
1 month-8.86%
3 months-15.93%
YTD-17.67%
1 year—
3 years—
5 years—